Thyme Care secures $60M in series B funding to scale cancer care beyond the clinic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Thyme Care raised $60 million in series B funding, co-led by Town Hall Ventures and Foresite Capital and with participation from current investors Andreessen Horowitz Bio + Health, AlleyCorp, Casdin Capital, and Frist Cressey Ventures. The capital brings Thyme Care’s total capital raised to over $80 million (The Cancer Letter, Oct. 7, 2022). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login